Physiomics plc
("Physiomics") or ("the Company")
Physiomics launches EasyAP™ a web-based version of its cardiac toxicity prediction service
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has now launched its predictive web-based platform for cardiac toxicity. EasyAP™ provides cardiac action potential time course simulations to facilitate the prediction of cardiac toxicity and compound selection.
Cardiac toxicity is a leading cause of attrition in clinical studies and post-marketing withdrawal. As an FDA requirement, all candidate drugs must be screened for activity against the hERG potassium channel. However, measurement of hERG activity is not sufficient to accurately predict cardiac toxicity. Physiomics' EasyAP™ takes into account activity against hERG and two additional ion channels to deliver action potential time courses and duration calculations based on several literature models.
This platform will allow a wider access to Physiomics existing cardiac toxicity prediction service. This will enable customers to access results immediately and significantly cut the time taken by Physiomics staff to perform such studies. To allow access to the service to a broad range of customers, the platform will allow customers to run simulations on their own computers on a "pay-as-you-go" or a subscription basis.
The cardiac toxicity platform can be accessed at www.easyap.co.uk.
Dr Mark Chadwick, CEO of Physiomics, commented:
"We are delighted to release this new web-based platform. A number of customers have indicated an interest in directly accessing such predictive models and we already have our first large pharma ready to sign up."
Enquiries:
Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980
WH Ireland Limited (broker/nomad)
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com
SystemCell® is a registered trademark of Physiomics plc
1Tufts Centre Impact Report 2002
